Cost–Effectiveness of Clopidogrel Plus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation in Whom Warfarin Is Unsuitable
- 作者Craig I. Coleman; Andrew D. Straznitskas; Diana M. Sobieraj; Jeffrey Kluger; Moise W. Anglade
- 卷第109卷
- 期第7期
- 印刷ISSN0002-9149
- 文件大小614.80KB
- 发表时间2012
- DOI10.1016/j.amjcard.2011.11.034
- 页码1020-1025
A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin Versus Aspirin AloneM.D. Schleinitz; P.A. Heidenreich · 2005
A Cost-Effectiveness Analysis of Combination Antiplatelet Therapy for High-Risk Acute Coronary Syndromes: Clopidogrel plus Aspirin versus Aspirin AloneSchleinitz, Mark D. · Annals of Internal Medicine · 2005
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: A cost-effectiveness analysisHemal Shah; Kathleen Gondek · 2000
Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA TrialJersey Chen; Deepak L. Bhatt; Elizabeth Schneider Dunn; Chunxue Shi; J. Jaime Caro; Elizabeth M. Mahoney; Sylvie Gabriel; Joseph D. Jackson; Eric J. Topol; David J. Cohen · 2009